![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Lisata Therapeutics Inc | NASDAQ:LSTA | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.045 | -1.31% | 3.385 | 3.31 | 22.00 | 3.40 | 3.36 | 3.40 | 3,817 | 05:00:00 |
BIO International Convention (June 3-6, 2024)Format: In-personLocation: San Diego, CaliforniaPresentation Date: Monday, June 3, 2024Presentation Time: 2:15 p.m. Pacific Time Presenter: David J. Mazzo, PhD, President and Chief Executive Officer of Lisata
Management will be available for one-on-one meetings with registered attendees. To schedule a meeting with the Company, please reach out to the Lisata representative under the contact section below or through the conference platform. For more information on the event, please visit https://convention.bio.org/.
GCFF 2024 Bio Investing ConferenceFormat: Virtual Presentation Date: Thursday, June 20, 2024Presentation Time: 10:00 a.m. Pacific Time Presenter: David J. Mazzo, PhD, President and Chief Executive Officer of Lisata
For more information on the conference and how to register, please visit https://www.eventbrite.ca/e/gcff-virtual-2024-bio-investing-conference-tickets-905051061087?aff=LSTA.
About Lisata Therapeutics
Lisata Therapeutics is a clinical-stage pharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. Lisata’s lead product candidate, certepetide (formerly LSTA1), is an investigational drug designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to selectively target and penetrate solid tumors more effectively. Lisata has already established noteworthy commercial and R&D partnerships based on its CendR Platform® technology. The Company expects to announce numerous milestones over the next two years and believes that its projected capital will fund operations into early 2026, encompassing anticipated data milestones from its ongoing and planned clinical trials. For more information on the Company, please visit www.lisata.com.
Contact:
Investors:
Lisata Therapeutics, Inc.John MendittoVice President, Investor Relations and Corporate CommunicationsPhone: 908-842-0084Email: jmenditto@lisata.com
Media:
ICR WestwickeElizabeth ColemanSenior AssociatePhone: 203-682-4783Email: elizabeth.coleman@westwicke.com
1 Year Lisata Therapeutics Chart |
1 Month Lisata Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions